Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 known ✓ | O60674 | 2/20 | 0.32 |
| ▸ | ABL1 known ✓ | P00519 | 2/20 | 0.32 |
| ▸ | RET known ✓ | P07949 | 2/20 | 0.32 |
| ▸ | FGFR1 known ✓ | P11362 | 2/20 | 0.32 |
| ▸ | PDGFRA known ✓ | P16234 | 2/20 | 0.32 |
| ▸ | FLT1 known ✓ | P17948 | 2/20 | 0.32 |
| ▸ | KDR known ✓ | P35968 | 2/20 | 0.32 |
| ▸ | ACVR1 known ✓ | Q04771 | 2/20 | 0.32 |
| ▸ | ROCK1 known ✓ | Q13464 | 2/20 | 0.32 |
| ▸ | ALK known ✓ | Q9UM73 | 2/20 | 0.32 |
| ▸ | PRKD3 known ✓ | O94806 | 1/20 | 0.32 |
| ▸ | NTRK1 known ✓ | P04629 | 1/20 | 0.32 |
| ▸ | MET known ✓ | P08581 | 1/20 | 0.32 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.32 |
| ▸ | PRKCQ known ✓ | Q04759 | 1/20 | 0.32 |
| ▸ | CSF1R known ✓ | P07333 | 1/20 | 0.31 |
| ▸ | NTRK2 known ✓ | Q16620 | 1/20 | 0.31 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3871102 | 0.98 | PNMT (0.37) | PNMTASIC3DYRK1AHTTKMT2A | |
| Hydrochloric Acid SCHEMBL31184489 | 0.83 | PNMT (0.49) | PNMTASIC3SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL30331878 | 0.83 | PNMT (0.49) | PNMTASIC3SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2262405 | 0.83 | PNMT (0.49) | PNMTASIC3SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL16935156 | 0.83 | PNMT (0.49) | PNMTASIC3SMN1; SMN2 | |
| SCHEMBL29762650 | 0.81 | PNMT (0.50) | PNMTASIC3 | |
| SCHEMBL21591692 | 0.81 | PNMT (0.50) | PNMTASIC3 | |
| SCHEMBL722943 | 0.81 | PNMT (0.50) | PNMTASIC3SMN1; SMN2 | |
| SCHEMBL29727983 | 0.81 | PNMT (0.50) | PNMTASIC3SMN1; SMN2 | |
| SCHEMBL6217721 | 0.80 | AURKA (0.34) | PNMTASIC3DYRK1AABHD6AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382308-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | NUEVOLUTION AS (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4419525-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2025-07-23 | — | — | EP | disclosed |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| EP-4511119-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | Nuevolution A/S (DK) | 2025-02-26 | — | — | EP | disclosed |
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| CN-119365455-A | Having a bromodomain active compounds | 纽韦卢森公司 | 2025-01-24 | — | — | CN | disclosed |
| EP-4419525-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| CN-118556059-A | Heterocyclic compounds for the treatment of cancer | 阿提奥斯医药有限公司 | 2024-08-27 | — | — | CN | disclosed |
| CN-112955446-B | 6-Fluoro-2-methylbenzo [ D ] thiazol-5-yl compounds | 伊莱利利公司 | 2024-07-12 | — | — | CN | disclosed |
| WO-2023205251-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | NUEVOLUTION A/S (DK) | 2023-10-26 | — | — | WO | disclosed |
| CN-112313228-A | Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2021-02-02 | — | — | CN | disclosed |
| US-20210024502-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2021-01-28 | — | — | US | disclosed |
| US-10870641-B2 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-10836773-B1 | 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds | ELI LILLY AND COMPANY (US) | 2020-11-17 | — | — | US | disclosed |
| US-10752632-B2 | 6-fluoro 2-methylbenzo[d]thiazol-5-yl compounds | ELI LILLY AND COMPANY (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200123134-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2020-04-23 | — | — | US | disclosed |
| WO-2020068530-A1 | 6-FLUORO-2-METHYLBENZO[D]THIAZOL-5-YL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2020-04-02 | — | — | WO | disclosed |
| US-20200095254-A1 | 6-Fluoro-2-Methylbenzo[d]thiazol-5-yl Compounds | ELI LILLY AND COMPANY | 2020-03-26 | — | — | US | disclosed |
| US-10550105-B2 | Pyridazinones as PARP7 inhibitors | Ribon Therapeutics Inc. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190330194-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10752632-B2 | 6-fluoro 2-methylbenzo[d]thiazol-5-yl compounds | MAPT, HTT, TFEB | JAK2 948/4885ABL1 640/4885RET 838/4885 |
| US-20210024502-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | JAK2 2244/4885ABL1 1004/4885RET 2740/4885 |
| US-20200095254-A1 | 6-Fluoro-2-Methylbenzo[d]thiazol-5-yl Compounds | MAPT, HTT, PSEN2 | JAK2 1095/4885ABL1 888/4885RET 1205/4885 |
| US-10550105-B2 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | JAK2 2244/4885ABL1 1004/4885RET 2740/4885 |
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | JAK2 2244/4885ABL1 1004/4885RET 2740/4885 |
| US-10836773-B1 | 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds | MAPT, HTT, PSEN2 | JAK2 1095/4885ABL1 888/4885RET 1205/4885 |
| US-20190330194-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | JAK2 2244/4885ABL1 1004/4885RET 2740/4885 |
| US-20250382308-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | BRD4, BRD3, EP300 | JAK2 1214/4885ABL1 461/4885RET 3885/4885 |
| US-10870641-B2 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | JAK2 2244/4885ABL1 1004/4885RET 2740/4885 |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NQO1, VHL, SDHA | JAK2 1113/4885ABL1 498/4885RET 861/4885 |
| US-20200123134-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | JAK2 2244/4885ABL1 1004/4885RET 2740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.